Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

A Study Evaluating HS-10370 Plus Platinum-based Doublet Chemotherapy With or Without Adebrelimab vs. Tislelizumab Plus Chemotherapy as First-Line Therapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer

11. september 2026 oppdatert av: Jiangsu Hansoh Pharmaceutical Co., Ltd.

A Randomized, Open-label, Controlled, Multicenter Phase 3 Trial of HS-10370 Plus Platinum-based Doublet Chemotherapy With or Without Adebrelimab vs. Tislelizumab Plus Chemotherapy as First-Line Therapy in Patients With Locally Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation.

This is a trial to evaluate the efficacy, safety, and tolerability of HS-10370 in combination with Platinum-based Doublet Chemotherapy With or Without Adebrelimab Versus Tislelizumab Plus Platinum-based Doublet Chemotherapy as first-line treatment in participants with previously untreated, locally advanced or metastatic NSCLC with KRAS G12C mutation

Studieoversikt

Status

Har ikke rekruttert ennå

Forhold

Intervensjon / Behandling

Studietype

Intervensjonell

Registrering (Antatt)

448

Fase

  • Fase 3

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

  • Voksen
  • Eldre voksen

Tar imot friske frivillige

Nei

Beskrivelse

Inclusion Criteria:

  • Participants are able to comply with the process of the protocol.
  • Men or women greater than or equal to 18 years
  • At least one measurable lesion in accordance with RECIST 1.1
  • Must have an ECOG performance status of 0 or 1.
  • Must have adequate laboratory parameters.
  • Patients with advanced solid tumors who have failed after adequate standard treatment, are intolerant to standard treatment, or have no standard treatment available.
  • Documentation of the presence of a KRAS G12C mutation
  • Reproductive-age women agree to use adequate contraception and cannot breastfeed while participating in this study and for a period of 6 months after the last dose.Men also consent to use adequate contraceptive method within the same time limit.

Exclusion Criteria:

  • Participants with tumors known to harbor molecular alterations for which targeted therapy is locally approved, except for KRAS G12C.
  • Treatment with any of the following: Previous or current treatment with other KRAS G12C inhibitors.
  • Active brain metastases.
  • Participants with uncontrolled pleural, ascites or pericardial effusion
  • History of other primary malignancies.
  • Abnormal cardiac examination results.
  • Severe, uncontrolled or active cardiovascular disorders.
  • Uncontrolled hypertension.
  • Severe bleeding symptoms or bleeding tendencies.
  • Severe arteriovenous thrombosis occurred
  • Serious infection.
  • Continuous use of glucocorticoids
  • Active infectious diseases.
  • Refractory nausea, vomiting, or chronic gastrointestinal diseases, or inability to swallow oral medications
  • Interstitial lung disease (ILD).
  • Serious neurological or mental disorders.
  • Active autoimmune diseases.

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: Randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Ingen (Open Label)

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: Arm A: HS-10370 plus Adebrelimab plus chemotherapy
Legemiddel: Karboplatin
Administreres intravenøst
Legemiddel: Cisplatin
Administreres intravenøst
Legemiddel: Pemetrexed
Administreres intravenøst
Legemiddel: HS-10370
Administered orally.
Legemiddel: Adebrelimab
Administered intravenously
Aktiv komparator: Arm B: Tislelizumab plus chemotherapy
Legemiddel: Karboplatin
Administreres intravenøst
Legemiddel: Cisplatin
Administreres intravenøst
Legemiddel: Pemetrexed
Administreres intravenøst
Legemiddel: Tislelizumab
Administreres intravenøst
Annen: Arm C: HS-10370 plus chemotherapy
Legemiddel: Karboplatin
Administreres intravenøst
Legemiddel: Cisplatin
Administreres intravenøst
Legemiddel: HS-10370
Administered orally.

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Progression-Free Survival (PFS)
Tidsramme: Randomization to first documented progression of disease or death from any cause. (Estimated as approximately 1 year)
Progression-Free Survival (PFS) PFS per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 by blinded independent central review (BICR)
Randomization to first documented progression of disease or death from any cause. (Estimated as approximately 1 year)

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Progression-Free Survival (PFS)
Tidsramme: Randomization to first documented progression of disease or death from any cause. (Estimated as approximately 1 year)
Progression-Free Survival (PFS) PFS per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 by Investigator
Randomization to first documented progression of disease or death from any cause. (Estimated as approximately 1 year)
Overall Survival (OS)
Tidsramme: Randomization to date of death from any cause. (Estimated as up to 3 years)
OS
Randomization to date of death from any cause. (Estimated as up to 3 years)
Overall Response Rate (ORR)
Tidsramme: Randomization to disease progression or death. (Estimated as approximately 1 year)
ORR per RECIST v1.1 by BICR and Investigator
Randomization to disease progression or death. (Estimated as approximately 1 year)
Duration of Response (DOR)
Tidsramme: Randomization to disease progression or death. (Estimated as approximately 1 year)
DOR per RECIST v1.1 by BICR and Investigator
Randomization to disease progression or death. (Estimated as approximately 1 year)
Number of Participants with a Treatment Emergent Adverse Event(s) (TEAE)
Tidsramme: Randomization to first documented progression of disease or death from any cause. (Estimated as approximately 1 year)
Number of Participants with a TEAE
Randomization to first documented progression of disease or death from any cause. (Estimated as approximately 1 year)

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Sponsor

Jiangsu Hansoh Pharmaceutical Co., Ltd.

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Antatt)

31. oktober 2026

Primær fullføring (Antatt)

31. mai 2030

Studiet fullført (Antatt)

31. desember 2031

Datoer for studieregistrering

Først innsendt

11. september 2026

Først innsendt som oppfylte QC-kriteriene

11. september 2026

Først lagt ut (Faktiske)

16. september 2026

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

16. september 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

11. september 2026

Sist bekreftet

1. september 2026

Mer informasjon

Begreper knyttet til denne studien

Ytterligere relevante MeSH-vilkår

Andre studie-ID-numre

  • HS-10370-301

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere